Atsena Therapeutics announces positive 12-month safety, efficacy Data from Phase I/II clinical trial of ATSN-101
Coverage of initial positive results from a clinical trial evaluating Atsena Therapeutics’ ATSN-101 gene therapy as a potential treatment for mutations to the gene GUCY2D that cause a form of inherited blindness known as Leber congenital amaurosis, or LCA, quotes Paul Yang, M.D., Ph.D., as saying “As LCA1 causes early and severe vision impairment or blindness and there are no approved treatments, ATSN-101 has the potential to fill a significant unmet need within the LCA community.”